IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide

MLA

Olivier Tournilhac, et al. “IGHV Gene Mutational Status and LPL/ADAM29 Gene Expression as Clinical Outcome Predictors in CLL Patients in Remission Following Treatment with Oral Fludarabine plus Cyclophosphamide.” Annals of Hematology, vol. 88, Apr. 2009, pp. 1215–21. EBSCOhost, https://doi.org/10.1007/s00277-009-0742-6.

APA

Olivier Tournilhac, Stéphane Leprêtre, Hélène Merle-Béral, Brigitte Dreyfus, Frederic Davi, Karim Maloum, Florence Nguyen-Khac, Beatrice Mahe, Claude Lesty, Catherine Settegrana, Bruno Cazin, Michel Leporrier, Elise Chapiro, & Alain Delmer. (2009). IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Annals of Hematology, 88, 1215–1221. https://doi.org/10.1007/s00277-009-0742-6

Chicago

Olivier Tournilhac, Stéphane Leprêtre, Hélène Merle-Béral, Brigitte Dreyfus, Frederic Davi, Karim Maloum, Florence Nguyen-Khac, et al. 2009. “IGHV Gene Mutational Status and LPL/ADAM29 Gene Expression as Clinical Outcome Predictors in CLL Patients in Remission Following Treatment with Oral Fludarabine plus Cyclophosphamide.” Annals of Hematology 88 (April): 1215–21. doi:10.1007/s00277-009-0742-6.